Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression

American Journal of Pathology

Volumn 144, Issue 1, 1994, Pages 70-81

  De Vries, Teunis J ^a   Quax, Paul H A ^b   Denijn, Marylène ^a   Verrijp, Kiek N ^a   Verheijen, Jan H ^b   Verspaget, Hein W ^c   Weidle, Ulrich H ^d   Ruiter, Dirk J ^a   Van Muijen, Goos N P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; POLYCLONAL ANTIBODY; PROTEINASE; RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CONTROLLED STUDY; DYSPLASTIC NEVUS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MELANOMA; METASTASIS; NEVUS CELL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STROMA CELL; TUMOR GROWTH;

EID: 0028363578     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Tryggvason K, Höyhthyä M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochem Biophys Acta 1987, 907:191-217
2. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993, 73:161-195
3. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. TIG 1990, 6:121-125
4. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985, 44:139-266
5. Pöllänen J, Stephens RW, Vaheri A: Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991, 50:273-328
6. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 1987, 69:81-387
7. Blasi F: Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988, 2:73-84
8. Stoppelli MP, Tachetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F: Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986, 45:675-684
9. Ellis V, Behrendt N, Danø K: Plasminogen activation by receptor-bound urokinase - a kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991, 266:12752-12758
10. Quax PHA, Pedersen N, Masucci MT, Weening-Verhoeff EJD, Danø K, Verheijen JH, Blasi F: Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 1991, 2:793-803
11. Miles LA, Plow EF: Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1991, 2:61-71
12. Stephens RW, Pöllänen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen EM, Rønne E, Behrendt N, Danø K, Vaheri A: Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989, 108:1987-1995
13. Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD: The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990, 111:783-792
14. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990, 9:1079-1085
15. Kohga S, Harvey SR, Suzumiya J, Sumiyoshi A, Markus G: Comparison of the immunohistochemical localization of urokinase in normal and cancerous human colon tissue. Fibrinolysis 1989, 3:17-22
16. Kohga S, Harvey SR, Weaver RW, Markus G: Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 1985, 45: 1787-1796
17. De Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Dooijewaard G, Van den Ingh HF, Lamers CBHW: Plasminogen activator profiles in neoplastic tissue of the human colon. Cancer Res 1988, 48:4520-4524
18. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990, 4:69-78
19. Duffy MJ, Reilly D, O'Sullivan C, O'Higgens N, Fennelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990, 50:6827-6829
20. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A: The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992, 50:871-873
21. Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM: Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 1989, 142:193-198
22. Sier CFM, Verspaget HW, Griffioen G, Verheijen JH, Quax PHA, Dooijewaard G, de Bruin PAF, Lamers CBHW: Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Gastroenterology 1991, 101:1522-1528
23. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983, 35: 611-619
24. Ossowski L: Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 1988, 52:321-328
25. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986, 47:487-498
26. Hearing VJ, Law LW, Corti A, Apella E, Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988, 48: 1270-1278
27. Axelrod JH, Reich R, Miskin R: Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H ras transformed NIH 3T3 cells. Mol Cell Biol 1989, 9:2133-2141
28. Miller SJ, Jensen PJ, Dzubow LM, Lazarus GS: Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not in basal cell carcinomas. J Invest Dermatol 1992, 89:351-358
29. Sappino A-P, Belin D, Huarte J, Hirschel-Scholz S, Saurai J-H, Vassalli J-D: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 1991, 88:1073-1079
30. Sier CFM, Fellbaum C, Verspaget HW, Schmitt M, Griffioen G, Graeff H, Höfler H, Lamers CBHW: Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology 1991, 19:231-237
31. Grøndahl-Hansen J, Ralfkiær E, Kirkeby LT, Kristensen P, Lund LR, Danø K: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991, 138: 111-117
32. Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K: Urokinase-type plasminogen is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991, 138:1059-1067
33. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K: The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991, 51:4067-4071
34. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA: Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992, 50: 208-209
35. Quax PHA, Van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Danø K, Ruiter DJ, Verheijen JH: Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor and urokinase mediated matrix degradation. J Cell Biol 1992, 115:191-199
36. Markus G, Kohga S, Camiolo SM, Madeja JM, Ambrus JL, Karakousis C: Plasminogen activators in human malignant melanoma. J Natl Cancer Inst 1984, 72: 1213-1222
37. Kwaan HC, Radosevich JA, Xu CG, Lastre C: Tissue plasminogen activator and inhibitors of fibrinolysis in malignant melanoma. Tumor Biol 1988, 9:301-306
38. Binnema DJ, Van Iersel JJL, Dooijewaard G: Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Tromb Res 1986, 43:569-577
39. Bos R, Siegel K, Otter M, Nieuwenhuizen W: Production and characterisation of a set of monoclonal antibodies against tissue-type plasminogen activator (t-PA). Fibrinolysis 1992, 6:173-182
40. Feinberg RF, Kao L-C, Haimowitz JE, Queenan JT, Wun T-C, Strauss JF, Kliman HJ: Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. Lab Invest 1989, 61:20-26
41. Van den Heuvel LPWJ, Van den Born J, Van de Velden TJAM, Veerkamp JH, Monnens LAH, Schröder CH, Berden JHM: Isolation and partial characterization of heparan sulfate proteoglycan from the human glomerular basement membrane. Biochem J 1989, 264:457-465
42. Quax PHA, Van Leeuwen RTJ, Verspaget HW, Verheijen JH: Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res 1990, 50:1488-1494
43. Sappino A-P, Huarte J, Vassalli J-D, Belin B: Sites of synthesis of urokinase and tissue-type plasminogen activator in the murine kidney. J Clin Invest 1991, 87: 962-970
44. Denijn M, De Weger RA, Berends MJH, Compier-Spies PhI, Jansz H, Van Unnik JAM, Lips CJM: Detection of calcitonin-encoding mRNA by radioactive and non-radioactive in situ hybridization: improved colorimetric detection and cellular localization of mRNA in thyroid sections. J Histochem Cytochem 1990, 38: 351-358
45. Hagège J, Peraldi MN, Rondeau E, Adida C, Delarue F, Medcalf R, Schleuning WD, Sraer JD: Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells. Am J Pathol 1992, 141:117-128
46. Ciambrone GJ, McKeown-Longo PJ: Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992, 267:13617-13622
47. Kost C, Stüber W, Ehrlich HJ, Pannekoek H, Preissner KT: Mapping of binding sites for heparin, plasminogen activator inhibitor-1 and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 1992, 267:12098-12105
48. Nakamura M, Konno H, Tanaka T, Maruo Y, Nishino N, Aoki K, Baba S, Sakaguchi S, Takada Y, Takada A: Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 1992, 65:709-719
49. Belin D, Wohlwend A, Schleuning WD, Kruithof EKO, Vassalli J-D: Facultative polypeptide translocation allows a single messenger RNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor-2. EMBO J 1989, 8:3287-3294
50. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172:902-908
51. Clark WH, Elder DE, Guerry D, Epstein ME, Greene MH, Van Horn M: A study of tumor progression; the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984, 15:1147-1156